Combined Metabolic Activator that includes Niagen in Mild-to-Moderate Alzheimer’s
WHY IS THIS IMPORTANT? Part of the ChromaDex External Research Program (CERP), this is a first-of-its-kind clinical study investigating the effects of a combined metabolic activator (CMA) featuring Niagen in 60 mild-to-moderate AD patients. The findings build on previous preclinical studies highlighting the benefits of this “ingredient cocktail” on AD, as well as on liver … Read more